ReNerve Limited (ASX: RNV) listed on the ASX in July 2023, positioning itself as a commercial-stage medtech company aiming to transform nerve repair through innovative tissue-engineered solutions. Less than two years later, the company has demonstrated consistent momentum in bringing its products to market, establishing international distribution networks, and expanding its product pipeline.